Fate Therapeutics (FATE) Tops Q2 EPS by 5c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $850.68 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• Destination XL Group names Jimmy Olsson as chief growth officer
• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE